Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Malignant pleural mesotheliomas (MPM) are most often surgically unresectable, and they respond poorly to current chemotherapy and radiation therapy. Between 23 and 64% of malignant pleural mesothelioma have somatic inactivating mutations in the BAP1 gene. BAP1 is a homologous recombination (HR) DNA repair component found in the BRCA1/BARD1 complex. Similar to BRCA1/2 deficient cancers, mutation in the BAP1 gene leads to a deficient HR pathway and increases the reliance on other DNA repair pathways. We hypothesized that BAP1-mutant MPM would require PARP1 for survival, similar to the BRCA1/2 mutant breast and ovarian cancers. Therefore, we used the clinical PARP1 inhibitors niraparib and olaparib to assess whether they could induce synthetic lethality in MPM. Surprisingly, we found that all MPM cell lines examined, regardless of BAP1 status, were addicted to PARP1-mediated DNA repair for survival. We found that niraparib and olaparib exposure markedly decreased clonal survival in multiple MPM cell lines, with and without BAP1 mutations. This clonal cell death may be due to the extensive replication fork collapse and genomic instability that PARP1 inhibition induces in MPM cells. The requirement of MPM cells for PARP1 suggests that they may generally arise from defects in HR DNA repair. More importantly, these data demonstrate that the PARP1 inhibitors could be effective in the treatment of MPM, for which little effective therapy exists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fenech, M., Kirsch-Volders, M., Natarajan, A. T., Surralles, J., Crott, J. W., Parry, J., Norppa, H., Eastmond, D. A., Tucker, J. D., & Thomas, P. (2011) · Mutagenesis · doi:10.1093/mutage/geq052 · Cited by 1,244 · cited 6×
“Fused chromosomes can have two centromeres, which would result in nuclear bridging, or no centromeres, which result in the chromosome being retained as micronuclei [20].”
MethodInfluentialGermline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
Cited by
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau‐Salle, F., Jablons, D., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21572 · Cited by 335
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1220 · Cited by 287
“Several studies proposed to test the efficacy of PARP inhibitors in mesothelioma, although patients were not selected for BAP1 status (136, 137).”
BackgroundFrequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
Panou, V., Gadiraju, M., Wolin, A., Weipert, C. M., Skarda, E., Husain, A. N., Patel, J. D., Rose, B., Zhang, S. R., Weatherly, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5204 · Cited by 229
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Nicolini, F., Bocchini, M., Bronte, G., Delmonte, A., Guidoboni, M., Crinò, L., & Mazza, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01519 · Cited by 83
MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers
Srinivasan, G., Williamson, E. A., Kong, K., Jaiswal, A. S., Huang, G., Kim, H.-S., Schärer, O., Zhao, W., Burma, S., Sung, P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903150116 · Cited by 28
Self-citation
Metadata
- Authors
- Srinivasan, G., Sidhu, G. S., Williamson, E. A., Jaiswal, A. S., Najmunnisa, N., Wilcoxen, K., Jones, D., George, T. J., & Hromas, R.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2017-07-29
- Volume
- 80
- Issue
- 4
- Pages
- 861-867
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2741664311
- Cited by
- 60
- References
- 3
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. https://app.cochat.ai/papers/10.1007/s00280-017-3401-y
- The paper
- Srinivasan, G., Sidhu, G. S., Williamson, E. A., Jaiswal, A. S., Najmunnisa, N., Wilcoxen, K., Jones, D., George, T. J., & Hromas, R. (2017). Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-017-3401-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.